Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.
Weekend warriors have a similarly low risk of disease and cardiometabolic health as those who spread exercise out evenly.
October 4, 2024 | Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.
Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback